ID

13663

Description

A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00001567

Lien

https://clinicaltrials.gov/show/NCT00001567

Mots-clés

Versions (1)
  1. 24/02/2016 24/02/2016 -
Téléchargé le

24 février 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Hairy Cell Leukemia NCT00001567

Anglais

Eligibility Hairy Cell Leukemia NCT00001567

1 Formulaires  
Criteria
Description

Criteria

patients must have morphologically identifiable hairy cells in peripheral blood and bone marrow, or tissue biopsies with at least one of the following: 1) positive stain for the tartrate-resistant acid phosphatase 2) electron microscopy compatible with hairy cells.
Description

hairy cells, tartrate resistant acid phosphatase positive

Type de données

boolean

Alias
UMLS CUI [1]
C0333850
UMLS CUI [2]
C0297331
UMLS CUI [3]
C0013842
patients must be ambulatory with an expected survival greater than 16 weeks and be willing and able to give written informed consent.
Description

ambulatory patients, life expectancy, informed consent

Type de données

boolean

Alias
UMLS CUI [1]
C0002423
UMLS CUI [2]
C0023671
UMLS CUI [3]
C0021430
patients must have a disease that is assessable, defined by: 1) pancytopenia 2) bone marrow leukemic infiltrate 3) lymphadenopathy, splenomegaly, or hepatomegaly.
Description

assessable disease, definition

Type de données

boolean

Alias
UMLS CUI [1]
C0030312
UMLS CUI [2]
C0346979
UMLS CUI [3]
C0497156
UMLS CUI [4]
C0038002 | C0019209
patients must not require palliative chemotherapy, immunotherapy or hormonal therapy other than the treatment prescribed in this protocol.
Description

palliative therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0030231
patients must be tested for hepatitis b surface antigen within one week of entry into this study.
Description

hepatitis b surface antigen

Type de données

boolean

Alias
UMLS CUI [1]
C0019168
no pregnant or lactating women. no fertile men and women, unless using effective contraception.
Description

pregnant or lactating, fertility, contraceptive methods

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0015895
UMLS CUI [4]
C0700589
no patients with unstable angina. patients with class iii or iv cardiovascular disease may be entered only after medical clearance by a cardiology consultant.
Description

unstable angina, cardiovascular disease

Type de données

boolean

Alias
UMLS CUI [1]
C0007222
no patients with severe intercurrent infection or patients having had surgery within the past four weeks unless fully recovered.
Description

infection, prior surgery

Type de données

boolean

Alias
UMLS CUI [1]
C0009450
UMLS CUI [2]
C0543467
no patients with impaired renal function (serum creatinine greater than 1.8).
Description

renal function, creatinine

Type de données

boolean

Alias
UMLS CUI [1]
C0232804
UMLS CUI [2]
C0201976
no patients with impaired hepatic function (total bilirubin greater than 1.4).
Description

hepatic function, bilirubin

Type de données

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C1278039
no patients with serum calcium greater than 12 mg/dl.
Description

serum calcium

Type de données

boolean

Alias
UMLS CUI [1]
C0728876
no patients with a performance status less than or equal to 60% on the karnofsky scale.
Description

karnofsky

Type de données

boolean

Alias
UMLS CUI [1]
C0206065
no patients who have had any prior (leukocyte or fibroblast) interferon therapy.
Description

interferon therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0279030
no patients unable to carry out the treatment program.
Description

able to carry out treatment program

Type de données

boolean

Alias
UMLS CUI [1]
C1321605
no patients less than 20,000 per cu mm platelets and clinical bleeding disorder; both must be present for patient to be excluded.
Description

platelets and blood coagulation disorder

Type de données

boolean

Alias
UMLS CUI [1]
C0005821
UMLS CUI [2]
C0005779
Retour au début de la page

Similar models

Eligibility Hairy Cell Leukemia NCT00001567

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
hairy cells, tartrate resistant acid phosphatase positive
Item
patients must have morphologically identifiable hairy cells in peripheral blood and bone marrow, or tissue biopsies with at least one of the following: 1) positive stain for the tartrate-resistant acid phosphatase 2) electron microscopy compatible with hairy cells.
boolean
C0333850 (UMLS CUI [1])
C0297331 (UMLS CUI [2])
C0013842 (UMLS CUI [3])
ambulatory patients, life expectancy, informed consent
Item
patients must be ambulatory with an expected survival greater than 16 weeks and be willing and able to give written informed consent.
boolean
C0002423 (UMLS CUI [1])
C0023671 (UMLS CUI [2])
C0021430 (UMLS CUI [3])
assessable disease, definition
Item
patients must have a disease that is assessable, defined by: 1) pancytopenia 2) bone marrow leukemic infiltrate 3) lymphadenopathy, splenomegaly, or hepatomegaly.
boolean
C0030312 (UMLS CUI [1])
C0346979 (UMLS CUI [2])
C0497156 (UMLS CUI [3])
C0038002 | C0019209 (UMLS CUI [4])
palliative therapy
Item
patients must not require palliative chemotherapy, immunotherapy or hormonal therapy other than the treatment prescribed in this protocol.
boolean
C0030231 (UMLS CUI [1])
hepatitis b surface antigen
Item
patients must be tested for hepatitis b surface antigen within one week of entry into this study.
boolean
C0019168 (UMLS CUI [1])
pregnant or lactating, fertility, contraceptive methods
Item
no pregnant or lactating women. no fertile men and women, unless using effective contraception.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0015895 (UMLS CUI [3])
C0700589 (UMLS CUI [4])
unstable angina, cardiovascular disease
Item
no patients with unstable angina. patients with class iii or iv cardiovascular disease may be entered only after medical clearance by a cardiology consultant.
boolean
C0007222 (UMLS CUI [1])
infection, prior surgery
Item
no patients with severe intercurrent infection or patients having had surgery within the past four weeks unless fully recovered.
boolean
C0009450 (UMLS CUI [1])
C0543467 (UMLS CUI [2])
renal function, creatinine
Item
no patients with impaired renal function (serum creatinine greater than 1.8).
boolean
C0232804 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
hepatic function, bilirubin
Item
no patients with impaired hepatic function (total bilirubin greater than 1.4).
boolean
C0232741 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
serum calcium
Item
no patients with serum calcium greater than 12 mg/dl.
boolean
C0728876 (UMLS CUI [1])
karnofsky
Item
no patients with a performance status less than or equal to 60% on the karnofsky scale.
boolean
C0206065 (UMLS CUI [1])
interferon therapy
Item
no patients who have had any prior (leukocyte or fibroblast) interferon therapy.
boolean
C0279030 (UMLS CUI [1])
able to carry out treatment program
Item
no patients unable to carry out the treatment program.
boolean
C1321605 (UMLS CUI [1])
platelets and blood coagulation disorder
Item
no patients less than 20,000 per cu mm platelets and clinical bleeding disorder; both must be present for patient to be excluded.
boolean
C0005821 (UMLS CUI [1])
C0005779 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial